ArticleMolecular and cellular biochemistry2006
Effect of different oral doses of isoniazid-rifampicin in rats.
Article in Molecular and cellular biochemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 34 citations in OpenAlex.
- Effect of Herbal Extracts on Antituberculosis Drug-Induced Hepatotoxicity: A Systematic Review.Journal of toxicology · 2026Article
- Combined in vivo and silico assessment of melatonin's protective effects on rifampicin-induced liver damage in rats.Scientific reports · 2025Article
- Article
- Amelioration of Nephrotoxicity in Mice Induced by Antituberculosis Drugs UsingInternational journal of nephrology · 2022Article
- Hepatoprotective Effect of Corm ofJournal of toxicology · 2021Article
- Lack of liver injury in Wistar rats treated with the combination of isoniazid and rifampicin.Molecular and cellular biochemistry · 2014Article
- Hepatoprotective agent tethered isoniazid for the treatment of drug-induced hepatotoxicity: Synthesis, biochemical and histopathological evaluation.Toxicology reports · 2014Article
- The Janeway gastrostomy tube for recurrent gastric intubations: a novel and simple animal model.Digestive diseases and sciences · 2008Article
- Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.In vivo (Athens, Greece)Article
- Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats.Indian journal of pharmaceutical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledHepatotoxicity is one of the most serious adverse effects of antituberculosis drugs. The aim of this study was to produce a rat model of isoniazid-rifampicin (INH-RIF) induced hepatotoxicity. MATERIALS AND
methodsWistar rats (100-150 g) were treated with different doses of INH i.e. 25, 50 and 75 mg/kg/day with a fixed dose of RIF i.e. 50 mg/kg/day intragastrically for a period of 28 days. Serum glutamate oxaloacetate aminotransferase (SGOT), glutamate pyruvate aminotransferase (SGPT), bilirubin (Bil) and alkaline phosphatase (ALP) were estimated at 0,14, 21 and 28 days in rats. Histological analysis was carried out to assess the liver.
resultsTreatment of rats with INH-RIF (50 mg/kg/day each) induced hepatotoxicity as judged by elevated serum SGPT, SGOT, Bil and ALP as compared with their base line. Histological evaluation of INH-RIF induced hepatotoxicity also showed liver damage.
conclusionThe present study suggests that 50 mg/kg/day each of INH-RIF was selected as hepatotoxic dose (i.e. minimum dose with maximum hepatotoxicity) in wistar rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.